Samantha Wade

Samantha Wade is a UOW PERL (Prioritising Emerging Research Leaders) Fellow at the University of Wollongong, where she is affiliated with the Faculty of Science, Medicine and Health and the School of Chemistry and Molecular Bioscience. She has held this research fellowship position since 2022, focusing on innovative approaches to cancer treatment through advanced drug delivery systems.

Dr. Wade's research centers on developing localized drug delivery systems to improve cancer treatment efficacy while minimizing systemic side effects. Her work particularly focuses on pancreatic cancer and breast cancer, with expertise in implantable drug delivery devices, biomaterials engineering, and immunotherapy delivery. She has made significant contributions to understanding how localized delivery of chemotherapeutic agents and immunotherapies can preserve gut microbiome integrity while enhancing anti-tumor responses. Her research bridges the gap between computational modeling, biomaterials science, and translational cancer research, with numerous publications demonstrating her expertise in wet-spun alginate fibers, coaxial drug delivery systems, and the relationship between drug delivery methods and tumor microenvironment dynamics.

Analysis of Dr. Wade's publication record reveals a strong progression from foundational in vitro studies to sophisticated in vivo models and computational approaches. Her work consistently demonstrates how implantable devices can deliver chemotherapeutics like gemcitabine and paclitaxel directly to tumor sites, improving efficacy while reducing systemic toxicity. A notable trend is her exploration of how these delivery systems interact with the gut microbiome, particularly examining how localized delivery preserves microbial diversity that is often disrupted by systemic chemotherapy. This research has important implications for improving patient outcomes by minimizing treatment-related toxicity and enhancing anti-tumor immunity.

Dr. Wade has secured several internal research grants at the University of Wollongong, including funding for advancing live cell imaging capabilities (2023), research on preventing immunotherapy hypersensitivity reactions in breast cancer models (2022), and a commercialization pathway grant associated with her PERL Fellowship (2021-2022) to translate drug delivery implants into clinical use. Her collaborative approach is evident through her numerous co-authorships across multiple disciplines, suggesting active participation in interdisciplinary research teams focused on cancer therapeutics. She maintains professional connections through X (Twitter) and collaborates with researchers across various institutions to advance her work in cancer treatment technologies.